Everything below concerns triagonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Reek of Putrefaction is the debut studio album by English extreme metal band Carcass. It was released by Earache Records on 28 July 1988. It is considered the first release in the goregrind genre, which the band pioneered.
Joanna Bryson and Helena Malikova have pointed to Big Tech's potential interest in promoting the AI Cold War narrative, as technology companies lobby for less onerous regulation of AI in the US and the EU. A factual assessment of the existing AI capabilities of different countries shows a less binary reality than portrayed by the AI Cold War narrative. The AI Cold War started as a narrative but it could turn into a self-fulfilling prophecy and fuel an arms race, not only because of corporate interests but also because of the existing interests at different national security departments. Regarding cyber power, the International Institute for Strategic Studies published a study in June 2021, which argued that the online capabilities of China have been exaggerated and that Chinese cyber power is at least a decade behind the US, largely due to lingering security issues.
Miso: A fermented soybean paste that is a cornerstone of Japanese cuisine. Its production involves combining koji (usually rice-based) with cooked soybeans and salt, followed by fermentation for weeks or even years. Enzymes in the koji break down complex proteins and carbohydrates in the soybeans, creating miso's rich and nuanced flavor. The fermentation time, type of koji, and additional ingredients all contribute to a wide variety of miso types, from sweet white miso to robust red miso. Miso adds depth and complexity to dishes such as soups, stews, marinades, and sauces. Sake: In sake production, koji converts rice starch into fermentable sugars. Unlike beer brewing, where saccharification and fermentation occur sequentially, sake brewing integrates these stages in a parallel fermentation environment. This dynamic interplay contributes to sake's unique flavor profile. Koji not only facilitates starch conversion but also develops nuanced aromas and flavors in the final product. Soy Sauce: A fermented condiment derived from soybeans and wheat, with koji initiating enzymatic breakdown. Koji is cultivated on roasted wheat and soybeans and then mixed with salt water to create a brine called moromi, which ferments for months. Koji enzymes break down proteins and starches, contributing to soy sauce's umami flavor. After fermentation, the moromi is pressed, pasteurized, filtered, and bottled.
2007 The book Ending Aging written by Aubrey de Grey and his research assistant Michael Rae. 2007 First evidence that a pharmacological agent (namely, metformin) at a certain dosage is capable to increase the lifespan of mice. 2008 Foundation of the Max Planck Institute for Biology of Ageing. 2008 (approximately) It was observed that different variants of FOXO3 gene are associated with human longevity. Since then, research has been conducted to better understand its functions and the mechanism of action. 2009 Association of genetic variants in insulin/IGF1 signaling with human longevity. 2009 A second pharmacological agent (namely, rapamycin) was shown to be capable to increase the lifespan of mice. For this discovery Dave Sharp receive a special prize from the Methuselah Foundation. 2009 The SENS Research Foundation, a research institute dedicated to studying the aging process and ways to reverse it based on the strategies for engineered negligible senescence approach, was established by Aubrey de Grey. 2010s first half The appearance of small political parties in different countries that make the promotion of anti-aging technologies part of their political platforms (for example, Science Party of Australia, U.S. Transhumanist Party, Party for Rejuvenation Research). 2010 Harvard University scientists at the Dana–Farber Cancer Institute partially reversed age-related degeneration in mice by engineering an improved telomerase gene. 2012 It was discovered that protein Sirtuin 6 (SIRT6) regulates the lifespan of male mice (but not female mice).
Sources: en.wikipedia.org
== Career in industry == Between the year 1947 and 1969, Beynon was Manager of Physics and Physical, Polymer and Analytical Chemistry at Imperial Chemical Industries. Between 1947 and 1950, Beynon constructed what was to become the first mass spectrometer designed to study organic compounds unrelated to petroleum. He subsequently collaborated with Metropolitan-Vickers to produce the MS8 mass spectrometer, a prototype of the Associated Electrical Industries (AEI) MS9 mass spectrometer. Beynon was made a senior research associate in 1964 which allowed him the opportunity to carry out his own research. He was a Boomer Memorial Fellow at the University of Minnesota in 1965.
=== Sales === The Valve Index headset, controllers, and base stations sold out in the US, Canada, and Europe within a week of the Alyx announcement. By mid-January 2020, they were sold out in all 31 regions. According to Superdata, Valve sold 103,000 Index units in the fourth quarter of 2019 as a result of the Alyx announcements, compared to the total 149,000 sold throughout 2019, and the Index was the highest-selling VR headset for PCs during that quarter. Though Valve had expected to supply several Index orders in time for the release of Alyx, the COVID-19 pandemic limited their supply chain. Valve's Greg Coomer said Valve knew many people would not play Alyx on launch and that its audience was "relatively small right now". Newell described it as a "forward investment" into long-term technologies. In 2021, PCGamesN wrote that though it was "artfully crafted", Alyx had had little cultural impact. As of December 2024, Alyx had sold more than two million copies.
==== Fat ==== Based on the findings that FNDC5 induces thermogenin expression in fat cells, overexpression of FNDC5 in the liver of mice prevents diet-induced weight gain, and FNDC5 mRNA levels are elevated in human muscle samples after exercise, it has been proposed that irisin promotes the conversion of white fat to brown fat in humans, which would make it a health-promoting hormone. While this proposal has been challenged by evidence finding FNDC5 is upregulated only in highly active elderly humans, more recent literature has supported the hypothesis of FNDC5 and irisin having a necessary role in exercise related benefits.
=== Available forms === Ceftriaxone is available for administration via the intramuscular or the intravenous routes. Ceftriaxone is stored as a dry powder in a vial, and is reconstituted (dissolved) immediately before use. The solution is used promptly after preparation, still, reconstituted solutions retain their physical and chemical stability for 24 hours at 25°C (or for 3 days when stored between 2 and 8°C). The solutions are pale yellowish in color, but the change of color to amber or reddish suggests hydrolysis of the amide bond of the β-lactam ring, thereby affecting the antimicrobial activity of the antibiotic. Diluents containing calcium are not used to reconstitute ceftriaxone, and it must not be administered in intravenous lines containing other calcium-containing solutions, as a ceftriaxone-calcium precipitate could form. This precipitation risk is particularly high in newborns (up to age 28 days), especially if they are premature or have impaired bilirubin binding. Beyond the approved intramuscular and intravenous routes, ceftriaxone has also been administered off-label via the subcutaneous route. This practice has been reported in multiple clinical series, particularly in elderly, frail, or palliative-care patients and in those with difficult venous access. Pharmacokinetic data and clinical observations suggest that subcutaneous ceftriaxone provides adequate systemic exposure and is generally well tolerated, with reported clinical effectiveness comparable to intravenous administration in selected, non–critically ill patients.
=== Olanzapine === Antipsychotic medications are increasingly used for schizophrenia, bipolar disorder, anxiety, and other psychiatric conditions Atypical antipsychotics are more commonly used than first generation antipsychotics because they decrease the risk of extrapyramidal symptoms, such as tardive dyskinesia, and have better efficacy. Olanzapine and atypical antipsychotics induce weight gain through increasing body fat. It also affects glucose metabolism, and several studies shows that it may worsen diabetes. A recent study shows that olanzapine inhibits GSK3 activity, suggesting olanzapine permits glycogen synthesis. A study of the effect of olanzapine on mouse blood glucose and glycogen levels showed a significant decrease in blood glucose level and elevation of glycogen level in mice, and the IC50% of olanzapine were 91.0 nm, which is considered a potent inhibitor. The study also illustrates that sub-chronic use of olanzapine results in potent inhibition of GSK3.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.